Accueil・Liste d'Actions・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Fermé

12.46 -1.97

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

12.22

Max

12.8

Chiffres clés
By Trading Economics
Revenu	-4.3M -18M
BPA	-0.19
Employés	37
EBITDA	-5.3M -17M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+141.21% upside

Dividendes
By Acuity
Prochains Résultats	3 nov. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-21M 1.1B
Ouverture précédente	14.43
Clôture précédente	12.46

Corvus Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

17 sept. 2026, 23:56 UTC

Targa Resources Corp is trading modestly higher in after-market hours, recovering from an early decline and reaching a high near the session's end.

17 sept. 2026, 23:56 UTC

Correlated Moves

Synaptics Inc declined during after-market hours, moving lower alongside the Nasdaq 100 Index amid positive economic data, including a drop in jobless claims.

17 sept. 2026, 23:56 UTC

TransUnion is trading modestly higher in after-market hours, despite earlier gains settling and the price remaining below its 20-day moving average.

17 sept. 2026, 23:56 UTC

Event

News

Rexford Industrial Realty completed a $1.2 billion sale of a 22-property portfolio to EQT Real Estate, with shares slightly declining in after-market trading.

17 sept. 2026, 23:56 UTC

Correlated Moves

Saia Inc's shares traded roughly flat during after-market hours, remaining below the 20-day moving average and near the lower end of its one-month range.

17 sept. 2026, 23:56 UTC

Fidelity National Information Services Inc is trading modestly higher in after-market hours following four consecutive sessions of losses, amid positive economic indicators.

17 sept. 2026, 23:52 UTC

Pinterest Inc is trading higher in after-market hours, continuing a trend of higher daily closes since Thursday's close, despite recent divergence from upward momentum.

17 sept. 2026, 23:51 UTC

Organon & Co. is experiencing a modest decline in after-market trading, remaining below its 20-day moving average and near the lower end of its one-month trading range.

17 sept. 2026, 23:51 UTC

Hawkins Inc is advancing in after-market trading, reaching its highest cumulative return of the day amid a one-month trading range.

17 sept. 2026, 23:51 UTC

Turning Point Brands Inc has advanced in after-market trading, recovering sharply from a low immediately following Thursday's close, contributing to an overall higher position.

17 sept. 2026, 23:51 UTC

TransDigm Group Inc is seeing modest gains in after-market trading, recovering from earlier lows but remains below its 20-day moving average.

17 sept. 2026, 23:51 UTC

American Electric Power Company Inc is trading modestly lower in after-market hours, continuing a decline from Thursday's close and remaining below its 20-day moving average.

17 sept. 2026, 23:51 UTC

Alliant Energy Corp is trading modestly higher in after-market hours, showing stability with slight upward movement and fluctuations within a narrow range.

17 sept. 2026, 23:51 UTC

Correlated Moves

BHP Group Ltd is advancing in after-market trading, reflecting a notable upward movement since Thursday's close, despite remaining below its 20-day moving average.

17 sept. 2026, 23:51 UTC

CRISPR Therapeutics AG declined modestly during after-market hours on Thursday, breaking a recent trend of higher daily closes.

17 sept. 2026, 23:51 UTC

Chicago Fed National Activity Index Release on September 21, 2026: Market Awaits Insights Amid Cautious Optimism and Inflation Concerns.

17 sept. 2026, 23:51 UTC

Mortgage Rates Hit 6.97%, Highest Since May 2025, as Market Sentiment Wanes Ahead of Upcoming MBA Release

17 sept. 2026, 23:51 UTC

Japan's Core Inflation Rate for August at 1.7% Falls Short of Expectations, Raising Concerns Over Economic Stability and Monetary Policy Effectiveness

17 sept. 2026, 23:51 UTC

Japan's August Inflation Rate at 1.9% Falls Short of Expectations, Raising Concerns for Monetary Policy Adjustments Amidst Weak Demand

17 sept. 2026, 23:51 UTC

Correlated Moves

Las Vegas Sands Corp is trading modestly higher in after-market hours, following a pullback earlier in the session, aligning with Wynn Resorts Ltd's gains.

17 sept. 2026, 23:51 UTC

Regeneron Pharmaceuticals Inc is trading modestly lower in after-market hours, remaining significantly below its 20-day moving average after a volatile session.

17 sept. 2026, 23:51 UTC

FedEx Corp is trading modestly lower in after-market hours, remaining significantly below its 20-day moving average and near the lower end of its one-month trading range.

17 sept. 2026, 23:51 UTC

ICU Medical Inc declined in after-market trading, reaching its lowest point shortly after the market closed and remaining below its 20-day moving average.

17 sept. 2026, 23:51 UTC

In after-market trading, Dave and Buster's Entertainment, Inc. is advancing, reflecting a notable increase since Thursday's close, despite being below its 20-day moving average.

17 sept. 2026, 23:51 UTC

SLB NV is trading modestly higher in after-market hours, following fluctuations that led to a cumulative return of 0.89% shortly after the market closed.

17 sept. 2026, 23:51 UTC

Correlated Moves

Cardinal Health Inc is trading modestly higher in after-market hours, following a slight uptick in Cencora Inc, which is recovering from recent declines.

17 sept. 2026, 23:51 UTC

Bath & Body Works Inc. is declining in after-market trading, currently near its lowest point of the day and below its 20-day moving average.

17 sept. 2026, 23:46 UTC

Ecolab Inc is trading modestly higher in after-market hours, though it remains below its 20-day moving average and near the lower end of its one-month range.

17 sept. 2026, 23:46 UTC

Daqo New Energy Corp is trading higher in after-market hours, closing at its highest point despite challenges, as U.S. jobless claims fell to 196k.

17 sept. 2026, 23:46 UTC

N-Able Inc gained in after-market trading, advancing since Thursday's close and stabilizing above its 20-day moving average near the upper end of its one-month range.

Comparaison

Variation de prix

Corvus Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

141.21% hausse

Prévisions sur 12 Mois

Moyen 29.5 USD 141.21%

Haut 33 USD

Bas 27 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

Achat

Maintien

Vente

Basé sur 4 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.